Integra LifeSciences (IART) investor relations material

Leadership and strategic direction

• Recent CEO transition has led to renewed focus on customer engagement, culture, and product comeback initiatives.

• Appointment of a chief commercial officer aims to present a unified enterprise face to customers and leverage contracting power.

• Emphasis on regaining customer confidence and winning back lost business through portfolio strength.

Product portfolio and market positioning

• PriMatrix was relaunched in late Q4 with strong customer reception; goal to recover about 50% of lost revenue by 2026.

• Portfolio includes products for wound, burn, trauma, plastics, and hernia, with plans to expand into implant-based breast reconstruction.

• Addressable market estimated at $2.5–$3 billion, with skin substitutes at $1.6 billion and hernia/breast reconstruction at $1.1 billion.

Market dynamics and reimbursement

• Business is 85% focused on inpatient reimbursement, largely insulated from recent CMS changes affecting outpatient and office-based care.

• Inpatient and DRG segments showed double-digit growth in Q1, while outpatient and physician office segments slowed.

• Company is educating hospital customers on reimbursement changes and monitoring opportunities in ambulatory and office settings.